Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
Semaglutide and tirzepatide, two headline glucagon-like peptide 1 receptor agonists (GLP-1RAs), are now facing a new wave of scrutiny: reports of hair loss in some research subjects. Prescription rates for these peptides are rising fast, and so are anecdotal mentions of telogen effluvium—a temporary shedding phase in the hair cycle—linked to their use. The research community wants answers.
Dermatol Ther (Heidelb)
by Piraccini BM, Vañó-Galván S, Blume-Peytavi U et al.
“Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Piraccini BM(1), Vañó-Galván S(2)(3), Blume-Peytavi U(4), Ribet V(5), Mengeaud V(6). Author information: (1)Private Dermatology Practice, Bologna, Italy. (2)Hair Disorders Unit, Dermatology Department, Ramon y Cajal Hospital, IRYCIS, University of Alcala, Madrid, Spain. (3)Grupo Pedro Jaen Clinic, Madrid, Spain. (4)Department of Dermatology, Venerology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany. (5)Medical Department, Laboratoires Ducray, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France. (6)Medical Department, Laboratoires Ducray, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France. valerie.mengeaud@pierre-fabre.com. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dual gastric inhibitory polypeptide (GIP)/GLP-1RAs are used to improve glycaemic control in patients with type 2 diabetes mellitus; some of these drugs are also used to help with weight loss. In recent years, safety signals concerning a possible link between GLP-1RA therapies and hair loss have been emerging in the USA. The volume of prescriptions for these drugs in Europe is now increasing, and it can be expected that the number of cases of GLP-1RA-associated hair loss will therefore also increase in Europe over the coming years. In this commentary, we consider the pharmacological context and market expansion for GLP-1RAs, examine the evidence for an association between GLP-1RAs and hair loss, explore potential pathophysiological mechanisms, and propose clinical recommendations. Most evidence suggesting a potential association between GLP-1RAs and hair loss comes from pharmacovigilance database analyses and retrospective cohort studies. No prospective, controlled studies have specifically evaluated this issue. The evidence suggesting an increased risk of hair loss is strongest for semaglutide and tirzepatide. However, although cases of hair loss have been noted across diverse settings and multiple analyses, causality has not been established. One potential underlying mechanism is the rapid weight loss seen with these drugs, which could induce telogen effluvium. Further research is needed to evaluate causality, underlying mechanisms, the role of dosing and route of administration, and patient factors that may increase the risk. Clinicians need to be aware of the possibility of hair loss occurring with GLP-1RAs and patients should be informed about the potential risk and monitored for hair loss. © 2026. The Author(s). Conflict of interest statement: Declarations. Conflict of Interest: Bianca Maria Piraccini has been a speaker and/or consultant for Almirall, Difa Cooper, Dercos-L’Oreal, Eli Lilly, ISDIN, Legacy Healthcare, Pierre Fabre-Ducray, Giuliani, Olistic, Pfizer. Sergio Vañó-Galván has received honoraria for lectures and consulting fees for acting as an advisor from Pierre Fabre. Ulrike Blume-Peytavi has been a speaker and/or consultant for Abbvie, Almirall, Cantabria Labs, Cassiopeia, CeraVe, Concert Pharmaceuticals/Sun Pharma, Cosmopharma, Dermocosmétique Vichy, Galderma Laboratorium GmbH, Eli Lilly, Legacy Healthcare, LEO-Pharma, Novartis, Pfizer, Sanofi Regeneron. Virginie Ribet and Valérie Mengeaud are employees of Pierre Fabre. Ethical Approval: Information presented in this article is based on previously conducted studies and it does not contain data from new studies with human participants or animals performed by any of the authors.”
Here’s what’s actually happening. Analysts have mined pharmacovigilance databases and retrospective cohort studies, flagging a possible association between GLP-1RAs and hair loss. Most of the data points towards semaglutide and tirzepatide. But here’s the catch: there are zero prospective, controlled studies targeting this question. Translation: we have signals, not certainty.
What’s the leading theory? Rapid weight loss—a common effect when these peptides are introduced—can kick off telogen effluvium. This isn’t unique to GLP-1RAs. Any sudden shift in body weight, calorie intake, or metabolic stress can trigger it. So far, no direct mechanism has been pinned to the peptides themselves.
Key takeaway:
Researchers haven’t established causality. The connection could be coincidental or indirect.
Cases have been observed across different studies and populations, but solid proof is missing.
More targeted research is needed to nail down mechanisms, dose dependence, and which subjects might be more likely to notice hair changes.
For researchers considering work with semaglutide or tirzepatide, being aware of these signals is smart. Monitoring for hair loss as part of routine outcomes makes sense, but there’s no reason to hit the panic button. As always, the peptide research community is best served by staying curious and following the evidence. Want to compare suppliers? Check the vendor directory for the latest research compound sources.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.